Trial Profile
Evaluation of red marrow aborbed dose of 177Lu-lilotomab satetraxetan in patients with B-cell non-Hodgkin lymphoma and correlation of these absorbed doses with hematologic toxicity
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 May 2017
Price :
$35
*
At a glance
- Drugs Lutetium-177 lilotomab satetraxetan (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions; Pharmacokinetics
- 25 May 2017 New trial record